Therapeutic Insights
Filter News
Found 967 articles
-
Researchers from around the world are coming to present scientific research and clinical trial data for the disease.
-
There are many challenges to tackling neurological diseases like Alzheimer’s, but one is the difficulty in developing drugs that can cross the blood-brain barrier. Researchers may have found a way around that problem.
-
Lilly Names HealthVoyager as Winner of Digital Health Innovation Challenge for Inflammatory Bowel Disease (IBD)
12/2/2019
Eli Lilly and Company's (NYSE: LLY) first digital health open innovation challenge, "Transforming IBD Care: Better Disease Monitoring, Management, and Care for People with Inflammatory Bowel Disease," has concluded, with HealthVoyager, an application developed by Boston Children's Hospital and Klick Health, being named the winner.
-
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
-
TauRx analyzed the relationship between the treatment doses, blood levels and pharmacological activity of the drug on the brain in more than 1,000 patients with mild-to-moderate Alzheimer’s disease as part of two Phase III global clinical trials.
-
Tecentriq is the company’s PD-L1 checkpoint inhibitor. Avastin is an antibody that binds to VEGF and interferes with tumor blood supply.
-
Researchers Working to Understand Why Some Patients with Autoimmune Diseases Develop Diabetes Ins...
11/21/2019
A peculiarity of autoimmune diseases is that they have many genes in common, but they develop differently. -
AR101 is an investigational, peanut-derived, biologic drug candidate for oral immunotherapy in patients with peanut allergy. It delivers a daily dose of peanut protein with a consistent protein profile.
-
$4.5 Million to Study How Neurovascular Dysfunction Contributes to Neurodegeneration in Alzheimer’s Disease
10/31/2019
NIH award supports collaborative work to discover the connection between neurovascular dysfunction and cognitive decline in Alzheimer’s disease.
-
Aimmune to Present New Data on Safety and Efficacy of AR101, Clinical Practice Implementation of Oral Immunotherapy, Quality of Life and Other Related Studies at ACAAI 2019
10/31/2019
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced it will present new data on the safety and efficacy of the company’s lead investigational candidate, AR101 (trade name Palforzia™), at the American College of Asthma, Allergy and Immunology (ACAAI) Annual Scientific Meeting, taking place November 7-11, 2019, in Houston
-
What is the best way to prevent or even reverse Alzheimer’s disease? That’s the question at the top of many researchers’ minds, especially given all of the recent large Phase 3 failures involving beta-amyloid targeting drugs, the most pursued target to date. This is troubling but not entirely sho...
-
Reuters reports that the turnaround was built on “top secret” meetings, non-disclosure agreements and six months of researchers, regulators and statisticians churning the data on a larger dataset that included a total of 3,285 patients.
-
The drug showed what the company is calling a “substantial improvement in this symptom-driven score” at the 12-week point, but it did not differentiate from placebo.
-
The decision was based on new analysis run by Biogen in consultation with the FDA of a larger dataset from the trials halted in March.
-
The trial met its co-primary endpoints, showing statistically significant and clinically meaningful improvements in overall survival and progression-free survival compared to standard-of-care, Bayer’s Nexavar.
-
Janssen Announces U.S. FDA Approval of STELARA® (ustekinumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis
10/21/2019
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration's (FDA) approval of STELARA® (ustekinumab) for the treatment of adult patients with moderately to severely active ulcerative colitis.
-
Retrospective Real-World Comparative Analysis Highlights Safety of Vedolizumab and Anti-TNFα Therapies in Biologic-Naïve Patients with Ulcerative Colitis or Crohn’s Disease
10/21/2019
Latest real-world data presented at UEG Week 2019 complements the extensive body of clinical evidence for the gut-selective biologic vedolizumab in biologic-naïve patients with moderately to severely active ulcerative colitis or Crohn’s disease
-
New Bay Area Spin-Off Company to Develop Drugs for Multiple Sclerosis and Alzheimer’s Disease
10/8/2019
The biotech company MedaRed, Inc. is founded on groundbreaking basic research from Gladstone Institutes, UC San Francisco, and UC San Diego.
-
Aimmune’s peanut allergy treatment is one-step closer to approval following strong support from the Allergenic Products Advisory Committee, which overwhelmingly recommended approval of Palforzia, the proposed trade name of the investigational oral treatment, AR101.
-
Bristol-Myers Squibb's Opdivo Fails to Show Superiority to Bayer's Nexavar in Liver Cancer
6/24/2019
The drug failed to meet statistical significance for overall survival. However, the company is putting a positive spin on it, saying it showed a clear improvement trend in OS for patients treated with Opdivo compared to sorafenib.